

**Revised Draft Agenda**  
**Biocides Working Group Meeting II-2024**  
**10–20 June 2024**

The time is indicated in Helsinki time.

10-11 June	10:00-18:00	APCP WG
12 June	10:00-18:00	APCP WG (reserve day)
14 June	10:00-18:00	In-situ
11-13 June	10:00-18:00	TOX WG
14 June	10:00-18:00	In-situ
18 June	10:00-18:00	TOX WG (reserve day)
11 June	10:00-17:00	EFF WG
13 June	10:30-18:00	EFF WG
14 June	10:00-18:00	In-situ
17 June	10:30-18:00	EFF WG
18 June	10:30-13:00	EFF WG (reserve day)
14 June	10:00-18:00	In-situ
17-19 June	10:00-18:00	ENV WG
20 June	10:00-18:00	ENV WG (reserve day)

## Analytical methods and physico-chemical properties Working Group

### Chair: Andreas Uphoff

Item 1 - Welcome and apologies	<i>For information</i>
Item 2 – Administrative issues	<i>For information</i>
Item 3 – Agreement of the agenda	<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda	<i>For information</i>
Item 5 – Agreement on the minutes of WG I 2024	<i>For agreement</i>
<b>Item 6 - Active Substances</b>	
6.1 Early WG on Muscalure (renewal)	<i>For agreement</i>
6.2 Early WG on Active chlorine generated from chloride of ambient water by electrolysis	<i>For agreement</i>
<b>Item 7 – Union Authorisations</b>	
7.1 UA family product containing Transfluthrin PT18	<i>This agenda item will not be discussed as there are no open points.</i>
7.2 UA family product containing L-(+)-lactic acid PT3	<i>This agenda item will not be discussed as there are no open points.</i>
7.3 UA family product containing Chlorocresol PT3	<i>This agenda item will not be discussed as there are no open points.</i>
<b>Item 8– Technical and guidance related items</b>	
8.1 In situ recommendations	<i>For discussion</i>
8.2 ACP guidance on point 15 of CA-Nov16-Doc.4.3-FinalRev 2 document regarding handling “carriers” in the authorisation of biocidal products	<i>For discussion</i>
8.3 Allocation of pre-soaked wipes to a certain formulation type	<i>For discussion</i>
8.4 Acceptable active substance degradation threshold during storage testing (overdosing)	<i>For discussion</i>
8.5 Worst case commercial packaging for storage testing	<i>For agreement</i>
8.6 TAB entry Role of water in peracetic acid solutions	<i>For agreement</i>
8.7 Waiving of test for self-reactive properties and explosive properties	<i>For discussion</i>
<b>Item 9– AoB</b>	
9.1 Nanomaterials and Biocides	<i>For information</i>
9.2 Review of e-consultations	<i>For information</i>
9.3 Other information	<i>For information</i>

Human Health Working Group Chair: Antero Airaksinen	
Item 1 - Welcome and apologies	
	<i>For information</i>
Item 2 – Administrative issues	
	<i>For information</i>
Item 3 – Agreement of the agenda	
	<i>For agreement</i>
Item 4 – Declarations of potential conflicts of interest in relation to the agenda	
	<i>For information</i>
Item 5 – Agreement on the minutes of WG I 2024	
	<i>For agreement</i>
Item 6 - Active Substances	
6.1 Early WG on in situ generated active bromine - ED assessment	
	<i>For agreement</i>
6.2 Early WG on Diuron - ED assessment	
	<i>For agreement</i>
6.3 Early WG on Dazomet renewal	
	<i>For agreement</i>
6.4 Early WG on chlorate as disinfection by-product in AS applications: * Sodium dichloroisocyanurate (NaDCC) anhydrous PT 2, 3, 4, 5, 11 * Sodium dichloroisocyanurate (NaDCC) dihydrate PT 2, 3, 4, 5, 11 * Trichloroisocyanuric acid (TCCA) PT 2, 3, 4, 5, 11	
	<i>For agreement</i>
Item 7 – Union Authorisations	
7.1 UA family product containing Transfluthrin PT 18	
	<i>For agreement</i>
7.2 UA family product containing L-(+)-lactic acid PT 3	
	<i>This agenda item will not be discussed as there are no open points.</i>
7.3 UA family product containing Chlorocresol PT 3	
	<i>This agenda item will not be discussed as there are no open points.</i>
7.4 Early WG on UA-APPs containing Icaridine, PT 19	
	<i>For agreement</i>
7.5 Early WG on QUAT-based products, PT 3, 4	
	<i>For agreement</i>

### **Item 8 – Article 75(1)(g) requests**

8.1 Salicylic acid ED assessment

*For agreement*

### **Item 9– Technical and guidance related items**

9.1 Cats and pyrethroids - warning sentences

*For agreement*

9.2 Field of use (HH and EFF joint session)

*For discussion*

9.3 In situ recommendations

*For discussion*

### **Item 10– AoB**

10.1 Other information

*For information*

## Efficacy Working Group Chair: Kasia Szymankiewicz

Item 1 - Welcome and apologies

*For information*

Item 2 – Administrative issues

*For information*

Item 3 – Agreement of the agenda

*For agreement*

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

*For information*

Item 5 – Agreement on the minutes of WG I 2024

*For agreement*

### Item 6 - Union Authorisations

6.1 UA family product containing Transfluthrin PT18

*This agenda item will not be discussed as there are no open points.*

6.2 UA family product containing L-(+)-lactic acid PT3

*This agenda item will not be discussed as there are no open points.*

6.3 UA family product containing Chlorocresol PT3

*This agenda item will not be discussed as there are no open points.*

6.4 Early WG on UA-APPs containing Icaridine, PT19

*For agreement*

6.5 Early WG on UA-APPs containing peracetic acid, PT2,3,4

*For agreement*

### Item 7 – Article 75(1)(g) requests

7.1 Formic acid, PT6

*For agreement*

7.2 1,2-Benzisothiazol-3-(2H)-one (BIT), PT6, 13

*For agreement*

### Item 8– Technical and guidance related items

8.1 Resistance draft guidance

*For discussion*

8.2 TAB proposal – Evaluation of PT 18 products against unicolonial ants

*For discussion*

8.3 Field of use (HH and EFF joint session)

*For discussion*

8.4 In situ recommendations

*For discussion*

8.5 TAB proposal - PT 11 freshwater and/or seawater-based systems

*For discussion*

**Item 9– AoB**

9.1 Other information

*For information*

## Environment Working Group Chair: Sander van der Linden

Item 1 - Welcome and apologies

*For information*

Item 2 – Administrative issues

*For information*

Item 3 – Agreement of the agenda

*For agreement*

Item 4 – Declarations of potential conflicts of interest in relation to the agenda

*For information*

Item 5 – Agreement on the minutes of WG I 2024

*For agreement*

### Item 6 - Active Substances

6.1 Early WG on in situ generated active bromine - ED assessment

*For agreement*

6.2 Early WG on active chlorine - ED assessment and waiving of data generation

*For agreement*

6.3 Early WG on Bronopol - Degradation in soil

*For agreement*

6.4 Early WG on Tosylchloramide sodium - ED assessment

*For agreement*

6.5 Icaridin - revision of toxicity data

*For agreement*

### Item 7 – Union Authorisations

7.1 UA family product containing Transfluthrin PT18

*For agreement*

7.2 UA family product containing L-(+)-lactic acid PT3

*This agenda item will not be discussed as there are no open points.*

7.3 UA family product containing Chlorocresol PT3

*This agenda item will not be discussed as there are no open points.*

7.4 Early WG on UA-APPs containing Icaridine, PT 19, ERA

*For agreement*

### Item 8 – Article 75(1)(g) requests

8.1 Salicylic acid ED assessment

*For agreement*

## Item 9– Technical and guidance related items

9.1 In situ recommendations

*For discussion*

9.2 Revision of ESD PT 18

*For agreement*

9.3 Degradation in manure

*For agreement*

9.4 Qualitative assessment of PAA and HP for releases via the municipal sewer system

*For agreement*

9.5 TAB entry for PEC soil RA considering NER

*For agreement*

9.6 Various exposure risk assessment items for agreement

*For agreement*

9.7 How to model emissions to groundwater from wood preservatives

*For agreement*

## Item 10– AoB

10.1 Other information

*For information*